Factors associated with multidrug-resistant bacteria in secondary peritonitis:: impact on antibiotic therapy

被引:54
作者
Seguin, P.
Laviolle, B.
Chanavaz, C.
Donnio, P. -Y.
Gautier-Lerestif, A. -L.
Campion, J. -P.
Malledant, Y.
机构
[1] Hop Pontchaillou, Serv Reanimat Chirurg, INSERM, U620, F-35033 Rennes 9, France
[2] Hop Pontchaillou, Ctr Invest Clin, INSERM 0203, F-35033 Rennes, France
[3] Hop Pontchaillou, Lab Bacteriol Virol, F-35033 Rennes 9, France
[4] Hop Pontchaillou, Serv Chirurg Digest, F-35033 Rennes 9, France
关键词
antibiotic resistance; multiresistance; peritonitis; risk-factors; therapy;
D O I
10.1111/j.1469-0691.2006.01507.x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Secondary peritonitis includes community-acquired and nosocomial peritonitis. These intra-abdominal infections have a common pathogenesis but some microbiological differences, particularly with respect to the type of bacteria recovered and the level of antimicrobial susceptibility. This report describes a prospective observational study of 93 consecutive patients with secondary peritonitis during an 11-month period. Community-acquired peritonitis accounted for 44 cases and nosocomial peritonitis for 49 cases (post-operative in 35 cases). Fifteen multidrug-resistant (MDR) bacteria were recovered from 14 patients. In univariate analysis, the presence of MDR bacteria was associated significantly with pre-operative and total hospital lengths of stay, previous use of antimicrobial therapy, and post-operative antimicrobial therapy duration and modifications. A 5-day cut-off in length of hospital stay had the best specificity (58%) and sensitivity (93%) for predicting whether MDR bacteria were present. In multivariate analysis, only a composite variable associating pre-operative hospital length of stay and previous use of antimicrobial therapy was a significant independent risk-factor for infection with MDR bacteria. In conclusion, knowledge of these two factors may provide a more rational basis for selecting initial antimicrobial therapy for patients with secondary peritonitis.
引用
收藏
页码:980 / 985
页数:6
相关论文
共 22 条
[1]  
[Anonymous], 1996, APIC INFECT CONTROL
[2]  
[Anonymous], 2001, ANN FR ANESTH S, V20, p350s
[3]   Acute renal failure: time for consensus [J].
Bellomo, R ;
Kellum, J ;
Ronco, C .
INTENSIVE CARE MEDICINE, 2001, 27 (11) :1685-1688
[4]   THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES, AND CLINICAL-TRIAL COORDINATION [J].
BERNARD, GR ;
ARTIGAS, A ;
BRIGHAM, KL ;
CARLET, J ;
FALKE, K ;
HUDSON, L ;
LAMY, M ;
LEGALL, JR ;
MORRIS, A ;
SPRAGG, R ;
COCHIN, B ;
LANKEN, PN ;
LEEPER, KV ;
MARINI, J ;
MURRAY, JF ;
OPPENHEIMER, L ;
PESENTI, A ;
REID, L ;
RINALDO, J ;
VILLAR, J ;
VANASBECK, BS ;
DHAINAUT, JF ;
MANCEBO, J ;
MATTHAY, M ;
MEYRICK, B ;
PAYEN, D ;
PERRET, C ;
FOWLER, AA ;
SCHALLER, MD ;
HUDSON, LD ;
HYERS, T ;
KNAUS, W ;
MATTHAY, R ;
PINSKY, M ;
BONE, RC ;
BOSKEN, C ;
JOHANSON, WG ;
LEWANDOWSKI, K ;
REPINE, J ;
RODRIGUEZROISIN, R ;
ROUSSOS, C ;
ANTONELLI, MA ;
BELOUCIF, S ;
BIHARI, D ;
BURCHARDI, H ;
LEMAIRE, F ;
MONTRAVERS, P ;
PETTY, TL ;
ROBOTHAM, J ;
ZAPOL, W .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (03) :818-824
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]   DEFINITION OF THE ROLE OF ENTEROCOCCUS IN INTRAABDOMINAL INFECTION - ANALYSIS OF A PROSPECTIVE RANDOMIZED TRIAL [J].
BURNETT, RJ ;
HAVERSTOCK, DC ;
DELLINGER, EP ;
REINHART, HH ;
BOHNEN, JM ;
ROTSTEIN, OD ;
VOGEL, SB ;
SOLOMKIN, JS .
SURGERY, 1995, 118 (04) :716-723
[7]   TIMENTIN IN THE ANTIMICROBIAL TREATMENT OF NOSOCOMIAL AND POLYMICROBIAL INFECTIONS [J].
CARLET, J ;
GOLDSTEIN, FW ;
BLERIOT, JP ;
BAHLOUL, F ;
DAZZA, FE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 :149-159
[8]  
Christou NV, 1996, ARCH SURG-CHICAGO, V131, P1193
[9]   Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial [J].
Dupont, H ;
Carbon, C ;
Carlet, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2028-2033
[10]  
*FRENCH SOC AN RES, 1999, CHIRURGIE, V124, P441